Merkliste 
 1 Ergebnisse 
 
1

Withdrawn: SGLT2 inhibitor ipragliflozin poses a low risk o..:

Tahara, Atsuo
Clinical and Experimental Pharmacology and Physiology.  49 (2022)  6 - p. 699-699 , 2022